TABLE 1.
Demographic and disease‐related characteristics of the survey participants
| Characteristic | |
|---|---|
| Women, n (%) | 199 (75.9) |
| Median (range) age, years | 42 (22–79) |
| Age <55 years, n (%) | 196 (74.8) |
| Associated comorbidities, n (%) | 66 (25.2)* |
| Hypertension | 32 (12.2) |
| Diabetes mellitus | 11 (4.2) |
| Lung disease | 5 (1.9) |
| Heart disease | 4 (1.5) |
| Obesity | 37 (14.1) |
| Malignancy | 4 (1.5) |
| Treated with DMTs, n (%) | 198 (75.6) |
| Natalizumab | 14 (7.1) |
| Ocrelizumab | 39 (19.6) |
| Dimethyl fumarate | 49 (24.7) |
| Teriflunomide | 19 (9.6) |
| Fingolimod | 26 (13.1) |
| Cladribine | 4 (2) |
| Glatiramer acetate | 27 (13.6) |
| Interferon beta 1a (Avonex) | 5 (2.5) |
| Interferon beta 1a (Plegridy) | 3 (1.5) |
| Interferon beta 1a (Rebif) | 9 (4.5) |
| Interferon beta 1b (Betaferon) | 3 (1.5) |
| Treated with corticosteroids in the past month before vaccination, n (%) | 17 (6.5) |
*Some participants reported more than one associated comorbidity.